European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
15 août 2024 04h30 HE
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, Iceland and LONDON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company...
Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea
15 août 2024 04h30 HE
|
Alvotech
Markaðsleyfi fyrir Evrópu gæti verið veitt á þriðja fjórðungi næsta árs Alvotech (NASDAQ: ALVO) og samstarfsaðili þess, alþjóðlega lyfjafyrirtækið Advanz Pharma tilkynntu í dag að Lyfjastofnun...
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
15 août 2024 04h30 HE
|
Alvotech
The approvals process is anticipated to be completed in the third quarter of 2025 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
01 août 2024 16h02 HE
|
Alvotech
REYKJAVIK, Iceland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech mun birta uppgjör fyrri árshelmings 2024 fimmtudaginn 15. ágúst nk. og streyma uppgjörsfundi föstudaginn 16. ágúst nk. kl. 12:00 að íslenskum tíma
01 août 2024 16h01 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrri helming ársins 2024 eftir lokun markaða í Bandaríkjunum, fimmtudaginn 15. ágúst nk. Þá mun Alvotech halda kynningarfund fyrir...
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
01 août 2024 16h01 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the...
STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu
22 juil. 2024 06h35 HE
|
Alvotech
Fréttatilkynning22. júlí 2024STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu Líftæknilyfjahliðstæðan kemur á markað um leið og einkaleyfi fyrir...
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
22 juil. 2024 06h35 HE
|
Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights...
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
22 juil. 2024 06h30 HE
|
Alvotech
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Alvotech Announces Closing of Private Debt Financing
11 juil. 2024 04h45 HE
|
Alvotech
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...